![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves New Nebulizer for Tyvaso Inhalation System
FDA Approves New Nebulizer for Tyvaso Inhalation System
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
October 25, 2017
United Therapeutics received FDA approval for its TD-300/A inhalation device for use with its Tyvaso (treprostinil) inhalation solution.
Tyvaso is a prostacyclin, pulmonary, and systemic vasodilator indicated for the treatment of pulmonary arterial hypertension to improve exercise ability.
Tyvaso was originally approved by the FDA for the treatment of PAH in 2009, under a new drug application covering a drug-device combination product consisting of Tyvaso drug product, as well as an ultrasonic nebulizer and accessories, referred to as the Tyvaso inhalation system.
Upcoming Events
-
21Oct